NanoString Technologies sees its recently launched nCounter Elements general purpose reagents as the "single most important launch" of its life science business in years, and believes that the availability of the new product will encourage adoption of NanoString's technology in the laboratory-developed testing market, according to the firm's CEO.

Brad Gray also told investors on an earnings call last week that the Seattle-based company is making progress toward launching its Prosigna Breast Cancer Test in the US by early 2014.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.